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FOXP3þCD25 Tumor Cells with Regulatory
Function in Se´zary Syndrome
Julia B. Heid1, Angelika Schmidt1, Nina Oberle1, Sergij Goerdt2, Peter H. Krammer1,
Elisabeth Suri-Payer1,3, Claus-Detlev Klemke1,2,3
Cutaneous T-cell lymphoma (CTCL) has been suggested by in vitro experiments to represent a malignant
CD4þ T-cell proliferation with a regulatory T-cell (Treg) phenotype (CD4þCD25þFOXP3þ ). We investigated
percentages of FOXP3þ and CD25þ cells in the blood of 15 Se´zary, 14 mycosis fungoides (MF), and 10 psoriasis
(Pso) patients and 20 normal healthy donors (NHDs). We found similar numbers of FOXP3þ cells in MF
(10.4% of blood CD4þ cells) and Pso (11.1%) patients and NHDs (9.8%). In 8 of 15 (53%) Se´zary patients,
significantly reduced percentages of FOXP3þ cells were seen in blood (2.9%) and skin (10.4%). Interestingly, 6 of
15 (40%) Se´zary patients showed significantly increased percentages of FOXP3þ cells (39.7% (blood), 20.3%
(skin)); however, these cells did not express CD25. In these latter patients, clone-specific TCR-Vb-chain
antibodies were used to demonstrate that these FOXP3þCD25 cells were monoclonal CTCL tumor cells.
FOXP3þCD25 CTCL tumor cells showed a highly demethylated status of the foxp3 gene locus similar to Treg
cells, and they were functionally able to suppress IL-2 mRNA induction in TCR-stimulated conventional T cells.
Thus, FOXP3þCD25 CTCL tumor cells with functional features of Treg cells define a subgroup of Se´zary
patients who might carry a different prognosis and might require differential treatment.
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INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) represent a
heterogeneous group of rare lymphoproliferative disorders
characterized by skin-homing monoclonal proliferations of
CD4þ T lymphocytes (Willemze et al., 2005). The major
variant is mycosis fungoides (MF), which is confined to the
skin and has a slowly progressing course over years to
decades. The less common Se´zary syndrome (SS) carries a
worse prognosis (Klemke et al., 2005) and is characterized
by erythroderma, generalized lymphadenopathy, and leuke-
mic blood involvement with 41000 Se´zary cells per ml
(Vonderheid et al., 2002). Both variants of CTCL are clini-
cally associated with a marked immunosuppression that is
often associated with a fatal outcome, especially in patients
with SS.
In 1995, Sakaguchi et al. identified CD4þCD25þ T cells
that control immune responses to non-self antigens by
suppressing conventional T-cell (Tcon) activity (Sakaguchi
et al., 1995). These suppressive cells represent a small subset
of T cells (approximately 10% of peripheral CD4þ T cells)
and were termed regulatory T (Treg) cells (Sakaguchi et al.,
2007; Sakaguchi and Powrie 2007). Treg cells are important
because depletion of CD25þ cells leads to a variety of
autoimmune inflammatory diseases, whereas reconstitution
with CD4þCD25þ T cells can inhibit disease development
(Setoguchi et al., 2005). In 2001, research on scurfy mice,
which spontaneously develop severe autoimmunity, showed
that the disease was due to a single mutation of the foxp3
gene on the X chromosome (Brunkow et al., 2001). Muta-
tions of the human foxp3 gene were found to be the cause
of a similar human disease called IPEX (immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked syndrome)
(Bennett et al., 2001). FOXP3 is abundantly expressed in
natural Treg cells, and is so far the most reliable molecular
marker for these cells (Roncador et al., 2005). However,
naive T cells in humans readily express FOXP3 upon TCR
stimulation, although the expression is generally much lower
and only transient compared with that of natural Treg cells
(Gavin et al., 2006; Pillai et al., 2007; Walker et al., 2003;
Yagi et al., 2004). Still, quantifying the degree of DNA
demethylation in the foxp3 locus enables differentiation
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between Treg cells and activated FOXP3þ Tcon cells (Baron
et al., 2007; Janson et al., 2008).
Despite their importance in controlling autoimmunity,
Treg cells can also suppress antitumor immune responses
in various cancers (Wang and Wang 2007). Therapeu-
tically, antitumor immune responses can be enhanced
after depletion of Treg cells during vaccination, for example,
in glioma patients (Grauer et al., 2008). Not only solid
tumors but also non-Hodgkin lymphomas can induce
functional Treg cells and thus worsen prognosis (Mittal
et al., 2008).
The fact that CTCL is a disease of malignant CD4þ T cells
associated with clinically evident immunosuppression made
it an interesting model for the investigation of various
immune functions. On the basis of in vitro cell culture
studies, Berger et al., 2005 suggested that CTCL represents a
malignant proliferation of Treg cells, which could explain its
immunosuppressive nature. This could not be immediately
confirmed in vivo, as multiple laboratories, including
our own, failed to demonstrate the FOXP3 expression of
skin-infiltrating CTCL tumor cells and, rather, showed that
FOXP3þ cells in MF skin lesions were bona fide Treg cells
(Banham et al., 2008; Gjerdrum et al., 2007; Klemke et al.,
2006). High numbers of FOXP3þ cells in skin specimens
from MF lesions correlated with early stages of MF and a
better prognosis than did MF skin infiltrates with fewer
FOXP3þ cells (Gjerdrum et al., 2007). However, a recent
study identified FOXP3þ CTCL tumor cells in the skin of
4 of 11 patients and the expression of low-molecular splice
forms of FOXP3 in the peripheral blood of 4 of 6 patients with
SS (Krejsgaard et al., 2008).
Here, we characterized Treg cells in the peripheral blood
of 29 CTCL patients by analyzing the expression of FOXP3,
CD25, and skin-homing markers. In a subgroup comprising
40% of our Se´zary patients, we found FOXP3 mRNA and
protein expressions of CTCL tumor cells, which were iden-
tified by monoclonal TCR-Vb-chain expression. FOXP3þ
CTCL tumor cells showed a highly demethylated status of
the foxp3 gene locus, similar to Treg cells. Finally, FOXP3þ
CTCL tumor cells isolated from Se´zary patients also showed
regulatory functions like those of Treg cells, as demon-
strated by the suppression of IL-2 mRNA induction in
TCR-stimulated Tcon cells.
RESULTS
CD4þCD25þFOXP3þ cells are not significantly reduced in
the peripheral blood of patients with SS compared with MF,
psoriasis, and healthy controls
To identify Treg cells in the peripheral blood of CTCL patients
and controls (normal healthy donors (NHDs) and psoriasis
(Pso)), we measured CD4, CD25, and FOXP3 expression by
flow cytometry, according to the strategy presented in
Supplementary Figure S1. In our previous study, we found a
lack of Treg cells in Se´zary patients, as demonstrated by the
CD4þCD25þ þ expression in the blood and the FOXP3
expression in the skin (Klemke et al., 2006). To better charac-
terize Treg cells in CTCL patients, we analyzed FOXP3
expression in the blood from Se´zary and MF patients and, as
controls, from Pso patients and NHDs. We found similar
percentages of FOXP3þ cells in NHDs (9.8±2.9% (SD) of
CD4þ cells, n¼20), MF (10.4±5.4%, n¼ 14) and Pso
(11.1±6%, n¼10) patients. Percentages of FOXP3þCD25þ þ
cells in NHDs (2.9±1.3%), MF (3.1±3.2%) and Pso
(3.7±4.3%) patients were also comparable (Figures 1a and b,
Table 1). In line with our previous findings (Klemke et al.,
2006), the percentages of FOXP3þ (4.4±23,9%, n¼15) and
FOXP3þCD25þ þ cells (0.4±2.4%) were reduced in Se´zary
patients (Figures 1a and b). However, these differences were
not significant because of the wide spread of values in the
Se´zary group.
Se´zary patients show heterogeneous expression levels of FOXP3
in peripheral blood and skin
A more detailed analysis of the Se´zary patient group revealed
two different subgroups. In all, 53% (8 of 15) of Se´zary
patients showed significantly reduced percentages of
FOXP3þ (2.9±1.3% of CD4þ cells) and FOXP3þCD25þ þ
cells (0.3±0.8%) (‘‘SS FOXP3 low’’) when compared with
those from NHDs (both Po0.05) and Pso and MF patients.
Interestingly, 40% (6 of 15) of Se´zary patients showed signi-
ficantly increased numbers of FOXP3þ cells (39.7±21.6%,
n¼6) (‘‘SS FOXP3 high’’), and a subset of these also
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Figure 1. Quantification of FOXP3þ and FOXP3þCD25þ þ Treg cells
in normal healthy donors (NHDs) and patients with SS, MF, and Pso.
The percentages of FOXP3þ Treg cells and FOXP3þCD25þ þ Treg cells
among CD4þ cells in different patient groups were measured using flow
cytometry according to the strategy presented in Supplementary Figure S1.
Every symbol represents a single individual (NHD, n¼18; SS, n¼13; MF,
n¼ 14; Pso, n¼ 10). The median for each group is shown by the black line.
Identification numbers of individual patients are shown in (c) and (d). No
significant differences could be detected between the groups as evaluated by
the Wilcoxon signed-rank test (a and b). (c) Further analysis of the SS patients
compared with NHDs revealed one group of patients with significantly
reduced numbers of FOXP3þ cells (‘‘SS FOXP3 low’’) and a second group
with significantly increased numbers of FOXP3þ cells (‘‘SS FOXP3 high’’),
*¼Po0.05. (d) The analysis of FOXP3þCD25þ þ cells also identified a ‘‘SS
FOXP3/CD25 low’’ and a ‘‘SS FOXP3/CD25 high’’ group compared
with NHDs, *¼ Po0.05 (d).
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had increased percentages of FOXP3þCD25þ þ cells (5.2±
0.8%, n¼3) in comparison with those from NHDs (both
Po0.05) (Figures 1c and d). Figures 2a and b show original
flow cytometry data in order to illustrate the varying levels of
FOXP3þ cells in CD4þ cells in different patients. In patient
SS1, we hardly detected any FOXP3þ cells, and the few that
were found were CD25(Figure 2a). In patient SS9, nearly
all CD4þ cells expressed FOXP3 at levels almost as high as
those in regular Treg cells (as can be noticed by the overlay
of CD4þ cells from an NHD, Figure 2b). Finally, in some
patients, for example, SS12, half of the CD4þ cells were
FOXP3þ . Interestingly, almost all FOXP3þ cells of the
patients were CD25, and the few FOXP3þCD25þ cells
detected probably reflect bona fide Treg cells. Only in
patients SS4, SS11, and SS15 did we find substantial levels of
CD25 on FOXP3þ cells. In addition, the percentage of
FOXP3þ cells also differs in the skin between the two Se´zary
patient groups, with a trend toward higher percentages of
skin-infiltrating FOXP3þ cells for the ‘‘SS FOXP3 high’’ group
(Table 1). ‘‘SS FOXP3 high’’ patients have a mean of
20.3±8.2% (range 11–31%) FOXP3þ cells of CD4þ cells
in the skin infiltrate in contrast to a mean of 10.4±5.3%
(range 7–18%, P¼ 0.063) FOXP3þ cells of CD4þ cells in
patients of the ‘‘SS FOXP3 low’’ group. This finding suggests
that in the ‘‘SS FOXP3 high’’ patients, CTCL tumor cells may
express FOXP3 in vivo, similar to what has been shown by
Berger et al., 2005 for CTCL cells after in vitro culture with
dendritic cells.
A subgroup of patients with SS has high numbers of FOXP3þ
CTCL tumor cells in the peripheral blood
The high number of FOXP3þ cells in the blood of almost half
of the Se´zary patients could be due to FOXP3 expression in
monoclonal CTCL tumor cells or to the expansion of
polyclonal natural Treg cells. To distinguish between these
possibilities, each Se´zary patient was screened with a panel
of TCR-Vb-chain antibodies as described elsewhere (Morice
et al., 2004). We were able to detect a predominant T-cell
population by an identical TCR-Vb-chain expression in 11 of
15 (73%) Se´zary patients (Table 1) as described previously,
because the panel of available TCR-Vb-chain antibodies
covers only about 70% of the TCR-Vb-chain repertoire
(Klemke et al., 2008; Morice et al., 2004; Morice et al.,
2006). In some Se´zary patients, the CTCL tumor cells as
identified by the identical ‘‘clonal’’ TCR expression also
express FOXP3 (Figure 3), but, interestingly, express very low
levels of CD25 (data not shown). In an NHD, as well as in
patient SS3, FOXP3þ cells were equally distributed within
the monoclonal and polyclonal T-cell populations, both
showing only a few FOXP3þ cells (Figures 3a and b). Patient
SS9 demonstrated an intermediate FOXP3 expression within
the ‘‘clonal’’ T-cell population (Figure 3c). Finally, a high
Table 1. Laboratory data of patients with Se´zary syndrome established at the time of this study
Patient
WBC
(4200–10200
per ll)
CD4
(400–1800
per ll)
CD4/CD8
(0.9–3.5)
Se´zary
cell
count (%)1
CD4+
CD7(per ll) TCR-R TCR-Vb
FOXP3+
cells per
ll Blood
FOXP3+
of CD4+
(%) Blood
FOXP3+
of CD4+
(%) Skin
SS1() 14900 7570 98 90 7483 mc Vb2 295 3.9 n.d.3
SS2() 8110 2097 5.6 46 1930 mc Vb18 82 3.9 6.9
SS3() 6540 1223 5.4 40 1024 mc Vb1 12 1 9
SS4(+) 4440 1347 6.4 60 1007 mc Vb7.1 283 21 25.6
SS5 51000 7678 97 70 6528 mc Vb17 n.d.3 n.d.3 n.d.3
SS6(+) 9850 3554 48,5 n.d.2 2955 mc Vb22 537 15.1 n.d.3
SS7() 11800 1399 5.2 10 25 mc Vb2 83 5.9 6.9
SS8() 5140 1453 19 23 1277 mc Vb1 70 4.8 7.5
SS9(+) 6180 1065 9.9 40 626 mc Vb18 969 91 15.6
SS10() 4900 1532 15.3 90 1435 mc – 35 2.3 n.d.3
SS11(+) 9240 1106 11.2 50 966 mc – 727 65.7 18.2
SS12(+) 4620 198 1.3 n.d.2 121 mc Vb2 116 58.5 31.4
SS13() 10400 4129 32 80 3890 mc – 70 1.7 n.d.3
SS14() 13500 2297 90 n.d.2 2070 mc Vb4 39 1.7 18.2
SS15(+) 10700 1269 7.2 6 192 mc – 335 26.4 10.8
mc, monoclonal; SS, Se´zary syndrome: (+)‘‘SS FOXP3 high’’; ()‘‘SS FOXP3 low’’; TCR-R, T-cell receptor rearrangement of peripheral blood mononuclear
cells; WBC, white cell blood count.
1Determined by peripheral blood smear.
2Not detectable by morphology.
3Not determined.
Ranges of normal values and used units are indicated in the first row.
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FOXP3 expression of all CTCL tumor cells was seen in patient
SS12 (Figure 3d). This finding was verified by staining with
two different FOXP3 antibodies (PCH101 and 236A/E/),
confirming its specificity (Tran et al., 2007) (Figure 3).
Furthermore, we excluded nonspecific Ab binding using
isotype control antibodies (data not shown). Finally, we were
able to identify increased Foxp3 mRNA expression levels in
TCR-Vb-chain CTCL tumor cells of ‘‘SS FOXP3 high’’ patients
that were sorted by fluorescence-activated cell sorting
(FACS), which were similar to those in expanded Treg cells
from NHD, although lower than in freshly isolated Treg
cells from NHD (Figure 4). Furthermore, the Foxp3 mRNA
expression levels of ‘‘SS FOXP3 high’’ patients were similar to
those of Tcon cells stimulated with a-CD3/a-CD28 for
15–23 hours. However, the FOXP3 mRNA expression in
activated Tcon cells was only transient and decreased below
that of unstimulated Tcon cells after 14 days (Figure 4).
FOXP3 protein expression was also seen in stimulated Tcon
cells, but to a lesser extent than in Treg cells (Figure 2c). In
addition, FOXP3 expression is stable in CTCL tumor cells, as
reanalyses of FOXP3 protein expression in several FOXP3þ
patients after a few months still yielded an identically high
FOXP3 expression in tumor cells (data not shown). In contrast
to this, the FOXP3 expression in Tcon cells was shown to be
only transient after in vitro activation (Figure 4 and Allan
et al., 2007; Pillai et al., 2007 and Walker et al., 2003).
Patients belonging to the ‘‘SS FOXP3 low’’ group were found
to express low levels of FOXP3 mRNA similar to shortly
stimulated (3 hours) or unstimulated Tcon cells from NHDs
(Figure 4). In summary, this clearly shows that in a subgroup
of 40% of Se´zary patients, CTCL tumor cells express FOXP3
mRNA and protein.
FOXP3þ CTCL tumor cells exhibit functions of naturally
occurring Treg cells
The fact that the ‘‘clonal’’ FOXP3þ cells of the ‘‘SS FOXP3
high’’ subgroup of Se´zary patients are CD25 argues for
the idea that these are CTCL tumor cells rather than expanded
Treg cells. However, Treg cells might lose CD25 expression
on prolonged proliferation. To test whether FOXP3þ CTCL
tumor cells (FOXP3þ ‘‘clonal’’ cells) might have origi-
nated from Treg cells or whether they gained the function
of Treg cells because of the expression of FOXP3, we
investigated whether they demonstrate the features and
functions of naturally occurring Treg cells. It was recently
shown that it is possible to distinguish Treg cells from
activated FOXP3þ Tcon cells by quantifying the degree of
DNA methylation in the human foxp3 locus (Baron et al.,
2007; Janson et al., 2008). We have used this technique
to investigate the methylation status of the foxp3 locus of
TCR-Vb-chain FACS-sorted CTCL tumor cells. Patients of
the ‘‘SS FOXP3 high’’ group demonstrated a highly demethyl-
ated foxp3 gene locus similar to that of Treg cells from
NHDs or an intermediate status of the foxp3 gene locus
with higher demethylation than in Tcon cells but less
than in Treg cells (Figure 5a). In contrast, ‘‘SS FOXP3 low’’
patients showed a similar methylation status of the foxp3
gene locus, as did Tcon cells from NHDs (Figure 5a).
Demethylation in FOXP3þ tumor cells can be observed
although the analyzed patients are all female, even though
one of the X-chromosomal foxp3 loci is usually silenced and
thus methylated. An aberrant methylation pattern does not
seem to be a general feature of Se´zary tumor cells, as it is
observed only in FOXP3þ and not in FOXP3 tumor
samples.
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Figure 2. FOXP3 and CD25 expression levels in patients with Se´zary syndrome (SS). FOXP3 expression was compared with CD25 expression of CD4þ
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donor (NHD) in a FOXP3 histogram overlay. (c) As a control, Tcon cells (Tcon) from an NHD were stimulated with a-CD3/a-CD28 for 15–72hours (one
representative donor shown) showing induction of FOXP3 in contrast to unstimulated Tcon cells, but to a lesser extent than was found in Treg cells (Treg).
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Recently our group demonstrated that Treg cells suppress
the induction of Th1 cytokine mRNA (for example, IL-2 and
IFN-g) of Tcon cells as early as 1 h after stimulation (Oberle
et al., 2007). Here, we tested the capacity of CTCL tumor
cells from both patient groups to suppress IL-2 mRNA
induction of Tcon cells after TCR stimulation. TCR-Vb-chain
FACS-sorted FOXP3þ CTCL tumor cells suppressed TCR-
induced IL-2 mRNA expression in Tcon cells to a similar
extent, as did naturally occurring Treg cells from NHDs
(Figure 5b). In contrast, FOXP3 CTCL tumor cells from
patients of the ‘‘SS FOXP3 low’’ group were not able to
suppress TCR-induced IL-2 mRNA induction in Tcon cells
(Figure 5b). Thus, FOXP3þ CTCL tumor cells have suppres-
sive function and a demethylated foxp3 gene locus, and are
therefore similar to naturally occurring Treg cells.
DISCUSSION
In this study, we provide evidence for FOXP3þ CTCL tumor
cells in vivo. In accordance with our previous results showing
a lack of CD4þCD25þ cells in Se´zary patients (Klemke
et al., 2006), we identified a subgroup of Se´zary patients
with significantly reduced percentages of FOXP3þ and
FOXP3þCD25þ cells in peripheral blood in contrast to
MF and Pso patients and NHDs. Interestingly, 40% of
Se´zary patients presented significantly increased numbers of
FOXP3þ and FOXP3þCD25þ cells in the blood, and also—
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Figure 3. In a subgroup of Se´zary (SS) patients, the cutaneous T-cell lymphoma (CTCL) tumor cells express FOXP3. Using a large panel of a-TCR-Vb-chain
mAbs, we first determined the appropriate mAb with which to detect clonal CTCL tumor cells. The mAb was then used in multicolor staining in combination
with FOXP3. The identical surface expression of a given TCR-Vb-chain within the lymphocyte population identifies CTCL tumor cells (CD4þTCR-Vbþ ; solid
square) and distinguishes them from the remaining polyclonal lymphocytes (CD4þTCR-Vb, dotted square). Both cell populations were analyzed for their
FOXP3 expression with two antibodies (PCH101 and 236A/E7). The results of a normal healthy donor (NHD) (a, in green) and of three SS patients (b–d, in red)
are shown. In the NHD, the solid gate identifies all TCR-Vb1þ cells that are of polyclonal nature and thus similar to the rest of the cells in the dotted gate, and
both populations therefore show identical FOXP3 expression patterns (a).
www.jidonline.org 2879
JB Heid et al.
FOXP3 Expression in Se´zary Syndrome Tumor Cells
to a lesser degree—in the skin. This could be attributable to
the fact that the majority of skin biopsies were taken at the
time of diagnosis, in contrast to most of the blood samples,
which were taken during the course of disease in order to
obtain fresh cells for flow cytometry and functional assays.
Our finding of FOXP3þ CTCL tumor cells supports and
extends a study that identified increased FOXP3 protein and
mRNA expression in the peripheral blood of 6 of 31 (20%)
Se´zary patients (Capriotti et al., 2008). This retrospective
study did not correlate FOXP3 expression with tumor cell
markers and did not analyze skin specimens. Krejsgaard et al.
(2008) used immunohistochemistry to detect the FOXP3
expression of skin-infiltrating CTCL tumor cells—identified
by morphology—and low-molecular splice forms of FOXP in
the peripheral blood of Se´zary patients. In our study, we
identified FOXP3 protein and mRNA expression in clonally
expanded CTCL tumor cells by using clone-specific TCR-Vb-
chain antibodies for co-stainings.
Similar to our results in Se´zary patients, it was shown
in several studies that adult T-cell leukemia/lymphoma cells
express FOXP3 (Chen et al., 2006; Karube et al., 2004;
Karube et al., 2008; Kohno et al., 2005; Matsubara et al.,
2005; Shimauchi et al., 2008; Abe et al., 2008). Interestingly,
some patients with adult T-cell leukemia/lymphoma
show clinical features similar to those of patients with MF
(Willemze et al., 2005). The FOXP3 expression of adult T-cell
leukemia/lymphoma tumor cells was shown to correlate with
infection by human T-lymphotropic virus-1 (Walsh et al.,
2006). Infection with Epstein–Barr virus might also lead to
FOXP3þ tumor cells, as observed in patients with post-
transplant lymphoproliferative disorder (Ebert et al., 2008).
However, infections with human T-lymphotropic virus-1 and
Epstein–Barr virus are usually not seen in Se´zary patients.
FOXP3 expression of tumor cells was recently also shown for
a number of solid tumors, including malignant melanoma,
prostate cancer, colon cancer, and, less frequently, in breast
cancer cell lines (Ebert et al., 2008). Thus, FOXP3 expression
is not restricted to Treg cells but is also seen in various tumor
cells.
CTCL tumor cells represent monoclonal proliferations
of CD4þ lymphocytes. Treg cells were shown to be a
subpopulation of CD4þ lymphocytes, characterized by
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FOXP3 mRNA at a level similar to that of expanded Treg cells. FOXP3 mRNA
levels were determined by quantitative reverse transcriptase –PCR in TCR-Vb-
chain CTCL tumor cells that were sorted by fluorescence-activated cell sorting
from FOXP3þ and FOXP Se´zary (SS) patients. As controls, normal healthy
donors (NHDs) were analyzed with regard to FOXP3 mRNA expression in
both unstimulated and a-CD3/a-CD28-stimulated Tcon cells (Tcon),
unstimulated Treg cells (Treg), and expanded Treg cells (3–23 hours and
14 days, expanded for 20 days with a-CD3, a-CD28, and IL-2). One
representative NHD is shown. Fold inductions relative to unstimulated
Tcon cells (set to 1) are denoted. All values were normalized to
glyceraldehyde-3-phosphate dehydrogenase, with error bars representing
the standard deviation of the mean. Subgroups of SS patients are
labeled (þ ) for ‘‘SS FOXP3 high’’ or () for ‘‘SS FOXP3 low.’’
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Figure 5. FOXP3þ CTCL tumor cells show DNA demethylation of the foxp3
gene locus and suppress IL-2 mRNA induction in TCR-stimulated Tcon cells
comparable to Treg cells from normal healthy donors. (a) Cell populations
were sorted by fluorescence-activated cell sorting according to their CD4 and
CD25 or TCR-Vb-chain expression. Total DNA from sorted cells was
extracted and subjected to bisulfite sequencing to assess CpG methylation of
the foxp3 gene locus. The methylation rate of characteristic CpG sequences in
the TSDR (Treg-specific demethylated region) of the Foxp3 gene, which
consists of amplicon 5, is depicted by the color scale. The DNA methylation
rate of three Se´zary patients (SS), as well as Treg and Tcon cells from a
representative NHD. (b) For suppression assays, responder Tcon cells from an
NHD were co-cultured with Treg cells (NHD) or Se´zary tumor cells in a 1:1
ratio and stimulated with a-CD3 and a-CD28. Responder Tcon cells alone,
either unstimulated (unstim.) or stimulated, were used as control. To exclude
cell density effects, double amounts of Tcon cells alone were also used as
control (not shown). Treg cells were isolated by flow sorting for expression of
CD4 and high expression of CD25, whereas Tcon cells were CD25 depleted
and CD4þ purified by MACS technology. After the co-culture assays,
responder Tcon cells were separated from Treg cells by staining for CD4 and
CD25 and from tumor cells by CD4 and TCR-Vb staining and subsequent flow
sorting. After stimulation with a-CD3 and a-CD28 for 5 hours, only Treg cells
express CD25, whereas Tcon cells are not yet positive for the activation
marker, CD25, on the surface. RNA was extracted from the responder Tcon
cells and subjected to quantitative reverse transcriptase–PCR. IL-2 mRNA
expression, normalized to glyceraldehyde-3-phosphate dehydrogenase, is
shown relative to unstimulated Tcon cells (set to 1). Error bars represent
standard deviations of the mean. Subgroups of SS patients are labeled with
(þ ) for ‘‘SS FOXP3 high’’ or () for ‘‘SS FOXP3 low.’’ n. a., not amplified.
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FOXP3 and CD25 expression. Therefore, the question was
whether CTCL tumor cells in Se´zary patients also express
CD25. We failed to detect high expression levels of CD25 in
the majority of patients, as almost all FOXP3þ cells of the
patients were CD25. Only in three patients did we find
substantial levels of CD25. Although FOXP3 binds to the
CD25 promoter and is therefore capable of inducing CD25
expression, FOXP3þCD25 cells with suppressive function
were also found in mice (Masteller et al., 2005; Wan &
Flavell 2005; Fontenot et al., 2003). It could be speculated
that control of the CD25 promoter by FOXP3 is lost in CTCL
tumor cells. Furthermore, Capriotti et al. (2008) presented
similar results in Se´zary patients with a high tumor burden. In
their study, 8 of 31 Se´zary patients showed CD25 expression
that did not always correlate with FOXP3 expression. The
expression of CD25 by circulating neoplastic cells of
leukemic CTCL seems to be low and quite variable (Jones
et al., 2004; Talpur et al., 2006; Waldmann et al., 1984).
The quantification of Foxp3 mRNA underscored our
protein data in that only ‘‘SS FOXP3 high’’ cells expressed
substantial amounts of Foxp3 mRNA. Foxp3 mRNA expres-
sion of those tumor cells was not as high as that in freshly
isolated Treg cells from NHD, but it was comparable to that
in Treg cells from NHDs, which were expanded in vitro for
2–3 weeks, and to Foxp3 mRNA expression levels detected in
15–23-hour TCR-stimulated Tcon cells. These data might be
indicative of a high expansion rate of CTCL tumor cells
in vivo.
CTCL tumor cells might have acquired FOXP3 expression
by activation. It was recently shown and confirmed by
us (Figures 2c and 4) that activated human Tcon cells
transiently express FOXP3 (Allan et al., 2007) and can gain
suppressive abilities (Pillai et al., 2007 and Walker et al.,
2003). Other investigators have shown that FOXP3 expres-
sion does not correlate with suppressive function (Tran et al.,
2007 and Zheng et al., 2008). Baron et al. (2007) found that
DNA demethylation of the foxp3 locus discriminates Treg
cells from activated FOXP3þ Tcon cells in that several
regions of the foxp3 locus are demethylated in Treg, but
methylated in Tcon cells. In particular, the TSDR (Treg-
specific demethylated region) of the foxp3 gene, which
consists of amplicon 5, was shown to be highly demethy-
lated, specifically in Treg cells. Representative patients
expressing FOXP3 exhibit a stronger demethylation of the
foxp3 locus than do Tcon and FOXP3 CTCL tumor cells,
the latter carrying a methylation pattern resembling the one
of Tcon cells. This indicates that the FOXP3 expression
observed in CTCL tumor cells in the ‘‘SS FOXP3 high’’ group
of Se´zary patients is due to the regulation of foxp3 gene
transcription and not (only) to altered stability of FOXP3
mRNA or protein. Another group demonstrated that the
features of Treg cells (FOXP3 expression and IL-10
production) were induced in CTCL tumor cells by common
g-chain-signaling cytokines, such as IL-2 and IL-15, and do
not represent a fully predetermined, constitutive phenotype
independent of the local environmental stimuli to which
these malignant CD4þ T cells become exposed, for example,
in the skin (Kasprzycka et al., 2008).
To determine whether FOXP3þ CTCL tumor cells
represent a malignant proliferation of Treg cells, functional
studies of their suppressive capacity are crucial. Because
CTCL tumor cells are difficult to cultivate in vitro, long-term
assays to assess suppressive activity, such as proliferation
assays, are difficult to perform. Therefore, we tested
suppressive capacity by analyzing IL-2 mRNA suppression,
which was shown to be suppressed in Tcon cells by Treg cells
within a few hours (Oberle et al., 2007). FOXP3þ CTCL
tumor cells from the ‘‘SS FOXP3 high’’ subgroup of patients
were able to suppress IL-2 mRNA induction in TCR-
stimulated Tcon cells in contrast to FOXP3 CTCL tumor
cells, which failed to do so. This clearly shows that FOXP3
expression of CTCL tumor cells is associated with Treg-like
functions. The functional relevance of FOXP3 expression for
the suppression of Tcon cells could be demonstrated in some
patients with adult T-cell leukemia/lymphoma (Chen et al.,
2006; Matsubara et al., 2005), but not in others (Shimauchi
et al., 2008). It remains an open question whether FOXP3þ
CTCL tumor cells are capable of suppressing an antitumor
immune response. However, normal Treg cells might control
tumor cell growth in CTCL patients, as reflected by the
association of high numbers of Treg cells with a better
prognosis in patients with MF and CD30þ CTCL (Gjerdrum
et al., 2007; Gjerdrum et al., 2008), in contrast to the more
aggressive course observed in Se´zary patients who lack
normal Treg cells (Klemke et al., 2006) or exhibit Treg cells
without suppressive activity (Tiemessen et al., 2006). Extra-
corporeal photopheresis has been used to treat SS for more
than 20 years. It was shown to induce antigen-specific Treg
cells in mice (Maeda et al., 2005), further supporting a
beneficial effect of Treg cells in the prognosis, course, and
treatment of CTCL. It can be speculated that TCR-specific
Treg cells might be able to specifically suppress the growth of
CTCL tumor cells and thereby control tumor-cell expansion
in the skin. This would be supported by the observation of a
better prognosis for CTCL patients with increased numbers of
Treg cells. In nonlymphoid cancer, Treg cells will not have a
direct influence on tumor cells, but they will inhibit the
T cells that should fight the cancer. In CTCL, it is possible that
a direct effect of Treg cells on tumor cells outweighs their
suppressive effect on the immune system in general.
The FOXP3þ CTCL tumor cells behave in a manner
functionally similar to Treg cells despite the fact that they
exhibit phenotypical differences (for example, in CD25
expression). It remains an open question whether FOXP3þ
CTCL tumor cells acquired FOXP3 expression either during
the natural course of the disease or because of the choice of
treatment. In our study population, we identified two
untreated Se´zary patients with FOXP3þ CTCL tumor cells
(Table 2). The majority of patients in both groups received
extracorporeal photopheresis and IFN-a, which makes it
difficult to identify a particular therapy leading to FOXP3
expression in tumor cells. Another point of interest is the
clinical relevance of our observation regarding prognosis and
response to treatment. We compared different clinical
parameters of ‘‘SS FOXP3 low’’ with ‘‘SS FOXP3 high’’
patients. We could not find significant differences between
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the two Se´zary patient groups in CTCL severity index, tumor
burden (CD4/CD8 ratio, number of circulating Se´zary cells),
and duration of disease. However, there seems to be a
trend toward a better prognosis for the ‘‘SS FOXP3 high’’
group. In this population, one of six patients died, whereas
four of eight patients in the ‘‘SS FOXP3 low’’ group
died (Table 2). Unfortunately, the two subgroups were too
small for a statistical comparison. In patients with MF and
CD30þ CTCL, high numbers of skin-infiltrating FOXPþ cells
were shown to be associated with a favorable prognosis
(Gjerdrum et al., 2007; Gjerdrum et al., 2008). Another study
found a worse prognosis for Se´zary patients with FOXP3
expression (Capriotti et al., 2008). The clinical relevance
of our findings needs to be confirmed in a larger cohort of
well-characterized Se´zary patients. The EORTC (European
Organization for Research and Treatment of Cancer)
cutaneous lymphoma task force is planning a multicenter
study to evaluate diagnostic markers, including FOXP3, in
SS, which could possibly answer the above-mentioned
questions.
Table 2. CTCL patients’ characteristics regarding clinical data, therapy, and outcome
Patient Age1 Gender Stage2 Duration of disease3 CTCL-SI4,5 Therapy5 Outcome
SS1() 63 M IVA 9 65 ECP Died
SS2() 62 F III 56 52 ECP, IFN-a PR
SS3() 56 M IVA 98 62 ECP, IFN-a Died
SS4(+) 66 M IVA 34 65 ECP, IFN-a, PUVA PR
SS5 70 F IVA 46 65 ECP, IFN-a, PUVA Died
SS6(+) 51 M III 30 55 Untreated SD
SS7() 82 M III 16 49 Untreated Died
SS8() 59 F IVA 76 65 ECP, IFN-a PR
SS9(+) 74 F IVA 55 73 ECP, IFN-a, PUVA PR
SS10() 69 F IVB 34 84 Alemtuzumab (a-CD52) Died
SS11(+) 79 M III 86 55 ECP, IFN-a Died
SS12(+) 86 F III 25 54 Topical steroids SD
SS13() 65 F IVA 14 65 ECP, IFN-a, PUVA PR
SS14() 71 M III 97 54 Topical steroids SD
SS15(+) 75 M III 19 50 Untreated CR
MF1 70 F IB 16 20 Untreated PR
MF2 38 M IB 41 17 UVB 311, topical steroids PR
MF3 37 F IB 48 14 Topical steroids PR
MF4 82 F IB 39 9 UVB 311, topical steroids PR
MF5 53 F IB 37 14 Topical steroids SD
MF6 67 F IB 168 6 Topical steroids PR
MF7 50 M IB 17 9 IFN-a, PUVA CR
MF8 76 M IB 301 6 Topical steroids, PUVA PR
MF9 71 M IB 181 3 Untreated CR
MF10 52 M IA 197 3 Topical steroids CR
MF11 71 M IB 169 11 Topical steroids PR
MF12 58 F IVA 243 0 Untreated CR
MF13 40 M IB 29 9 Topical steroids CR
MF14 80 F IB 37 6 UVB 311 PR
CR, complete remission; ECP, extracorporeal photopheresis; f, female; IFN, interferon; m, male; MF, mycosis fungoides; PR, partial remission; PUVA,
psoralen+UVA; SD, stable disease; SS, se´zary syndrome: (+), ‘‘SS FOXP3 high’’; (), ‘‘SS FOXP3 low’’; TNM, tumor node metastasis.
1In years.
2According to the TNM classification (Bunn and Lamberg, 1979).
3In months.
4According to Klemke et al. (2005).
5At the time of this study.
Cut-off date: 31 March 2008.
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In conclusion, in a subgroup of Se´zary patients, CTCL
tumor cells show FOXP3 expression and Treg-like functions,
for example, foxp3 gene locus demethylation and suppres-
sion of IL-2 mRNA in TCR-stimulated Tcon cells. FOXP3þ
CTCL tumor cells differ from Treg cells in an inconsistent
CD25 expression and a lower Foxp3 mRNA expression. The
modulation of FOXP3 expression in leukemic T cells could
be implicated in oncogenesis and potentially has a useful
clinical role. It has to be elucidated whether the FOXP3
expression of CTCL tumor cells is of prognostic relevance,
and whether FOXP3 expression is acquired or whether CTCL
represents a malignant expansion of Treg cells. Thereafter, it
should be possible to develop new treatment options that
target CTCL tumor cells more specifically.
PATIENTS AND METHODS
Patients
A total of 29 CTCL patients diagnosed according to the
WHO (World Health Organization)–EORTC classification of
cutaneous lymphomas (Willemze et al., 2005), the tumor-
node-metastasis staging classification (Bunn and Lamberg,
1979), and the criteria of the International Society of
Cutaneous Lymphomas (Vonderheid et al., 2002) were
included in the study, representing MF stages IA (n¼ 1), IB
(n¼12), and IVA (n¼ 1) and SS stages III (n¼ 7), IVA (n¼ 7),
and IVB (n¼ 1) (Table 2). For controls, we investigated blood
samples from Pso patients (n¼10) and NHDs (n¼20).
Informed consent was obtained from all participants before
inclusion. The study was conducted according to the ethical
guidelines at our institution and the Helsinki Declaration, and
approved by the Ethics Committee II of the Ruprecht-Karls-
University of Heidelberg, Germany.
Cell isolation, antibodies, flow cytometry, and histology
Peripheral blood lymphocytes were separated by Ficoll
gradient centrifugation and monocyte depletion. The follow-
ing antibodies were used for staining of the lymphocytes as
previously described: a-CD4-PerCp, a-CD25-APC-Cy7 (BD
Pharmingen, Heidelberg, Germany), a-CLA-FITC (Miltenyi
Biotec, Bergisch Gladbach, Germany), and a-FOXP3-APC
(clones PCH101 and 236/E7, eBioscience, Heidelberg,
Germany) (Fritzsching et al., 2005; Oberle et al., 2007).
Flow cytometry was carried out on a FACSCanto II (Becton
Dickinson, Heidelberg, Germany), and data were analyzed
using FACSDiva and CellQuest software (Becton Dickinson).
For RNA and DNA analyses, cells were sorted using CD4,
CD25, and TCR-Vb-chain (Immunotech/Beckman Coulter,
Fullerton, CA) expression with a FACS DIVA sorter (Becton
Dickinson). For suppression assays, Treg and Tcon cells were
isolated using MACS technology by CD4 and CD25
expression (Miltenyi Biotec) (Fritzsching et al., 2005; Oberle
et al., 2007).
Skin biopsies were taken at the first presentation of the
patients before onset of treatment and were fixed in formalin.
Hematoxylin and eosin, CD4 (clone 1F6, Novocastra,
Newcastle Upon Tyne, UK), and FOXP3 stainings were
carried out as described elsewhere (Poenitz et al., 2003;
Klemke et al., 2006; Roncador et al., 2005). All specimens
were blinded and analyzed as previously described (Dje-
madji-Oudjiel et al., 1996; Klemke et al., 2006).
Cell culture
Freshly isolated T cells were cultured in X-Vivo-15 medium
(Cambrex, Verviers, Belgium) supplemented with 1% Gluta-
max (Invitrogen, Karlsruhe, Germany). Treg cells were either
used immediately or stimulated overnight with 1 mgml1
a-CD3 and 50Uml1 IL-2, or expanded for up to 3 weeks
with 0.1 mgml1 a-CD3, 300Uml1 IL-2, and 1 mgml1
a-CD28, and re-stimulated every week.
DNA preparation and foxp3 promoter methylation analysis
Genomic DNA from freshly prepared, FACS-sorted cells was
isolated using the DNeasy tissue kit (Qiagen, Hilden,
Germany) following the manufacturer’s protocol. Analysis
of the DNA methylation status of the foxp3 locus was carried
out using bisulfite sequencing by Epiontis, Berlin, Germany
as previously explained (Baron et al., 2007).
Suppression assay, RNA preparation, and quantitative FOXP3
and IL-2 reverse transcriptase–PCR
The assays were carried out as previously described (Oberle
et al., 2007). Briefly, freshly isolated HLA-A2– CD4þCD25–
(Tcon) and HLA-A2þ CD4þCD25high (Treg) or CTCL tumor
cells were cultured alone or together in a 1:1 ratio and
stimulated with soluble a-CD3 (0.2 mgml1) and a-CD28
(0.5 mgml1) mAbs. After stimulation for 3–5 hours, the cells
were labeled with antibodies against CD4, CD25, HLA-A2,
and the respective TCR-Vb-chain for CTCL tumor cells,
separated by cell sorting on a FACS DIVA, and immediately
lysed in RNA extraction lysis buffer. RNA isolation, cDNA
preparation, and quantitative PCR were performed as
described elsewhere (Fritzsching et al., 2005; Oberle et al.,
2007).
Statistical analysis
Data are presented as individual values and as mean or
median. The Wilcoxon signed-rank test was used to compare
the results of the various patient groups, including multiple
comparisons. The test was considered significant with
Po0.05.
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